Phaseline

Companies › Guangzhou Patronus Biotech

Guangzhou Patronus Biotech: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 4 Phase 1, 2 Phase 2; Infectious disease, Vaccines; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LYB004
Recombinant varicella zoster virus glycoprotein E (VZV-gE) vaccine adjuvanted with A01B or
VZVPhase 2Herpes Zoster (HZ); Herpes ZosterDec 2026
LYB005
Recombinant Respiratory Syncytial Virus (RSV) vaccine
–Phase 2Respiratory Syncytial Virus Infection Prevention; Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus InfectionDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06335849LYB004Phase 1Herpes ZosterInfectious diseaseSep 2025
NCT06442241LYB005Phase 1Respiratory Syncytial Virus (RSV)Infectious diseaseDec 2025
NCT06874842LYB004Phase 1Herpes Zoster (HZ)Infectious diseaseFeb 2026
NCT06904222LYB005Phase 1Respiratory Syncytial Virus InfectionInfectious diseaseAug 2026
NCT07311148LYB004Phase 2Herpes Zoster (HZ)VaccinesDec 2026
NCT07208461LYB005Phase 2Respiratory Syncytial Virus Infection PreventionInfectious diseaseDec 2026

Targets

VZV (1)

Companies with the same targets

MAXVAX Biotechnology Limited Liability Company Green Cross

Companies built like this

Green Cross Aribio Lab Dynavax Technologies Osivax Artcline

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.